Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects - Trial NCT04588727
Access comprehensive clinical trial information for NCT04588727 through Pure Global AI's free database. This Phase 1 trial is sponsored by AstraZeneca and is currently Recruiting. The study focuses on Cardiovascular Disease. Target enrollment is 103 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
AstraZeneca
Timeline & Enrollment
Phase 1
Oct 15, 2020
May 20, 2022
Primary Outcome
Number of subjects with adverse events and serious adverse events in both Part A and Part B
Summary
Part A of this study is a Phase 1, First-in-human (FiH), randomized, single-blind, placebo
 controlled study to assess the safety, tolerability, pharmacokinetics (PK), and
 pharmacodynamics (PD) of AZD3366 following single intravenous (IV) ascending doses.
 
 Part B of this study is a randomized, single-blind, parallel group placebo-controlled study
 to assess the safety, tolerability and PD of a single IV administration of AZD3366 with
 concomitant loading doses followed by repeated maintenance dosing of ticagrelor and
 acetylsalicylic acid (ASA).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04588727
Non-Device Trial